NEWS. When Sciety was founded in 2014, the vision was clear – to bridge the gap between scientific breakthroughs and societal benefit. Ten years later, we have grown to become one of the Nordic region’s leading investors in life science and digital health, with over one billion SEK invested in 26 innovative companies.
From idea to established player in life science
Sciety was founded in late 2014 with the goal of financing and supporting life science companies. After about a year of preparation and business development, during which we got to know the ecosystem and the needs of investors, we were able to begin financing our first companies in 2016.
The journey began with the idea of a crowdfunding platform, but through a strong focus on quality and thorough evaluation, Sciety quickly developed into a respected player for professional investors. Today, we operate like a venture capital firm, focusing on innovations in life science and health tech.
“It feels significant when looking back. We started without connections, without investors, and without funding. Today, we are a well-established player in the industry, but with the same vision and values as we had from the start – to invest in and support leading companies within life science and health tech with both capital and network,” says Malin Lindblom, Managing Partner and Co-founder.
Life science investor Bengt Julander recognised Sciety’s potential early on. Bengt invested in Sciety in 2018 through Linc, now a publicly listed company, and has been an advisor since then. Last year, the board was strengthened when Tommi Unkuri – Partner and Co-founder of private equity firm Summa Equity – was elected.
Today, Sciety is a driving force in the development of Swedish life science. With investments of 1 billion SEK in 26 growth companies and strong annual returns, we have proven that it’s possible to combine societal impact with solid financial performance.
“Our grant from Vinnova when we were relatively new was important. During the application interview, we said we wouldn’t disappoint them, that we would do a lot for Swedish life science and promised to more than reciprocate the million we applied for. Now we have given back more than 1 billion in investments in Swedish life science and health tech companies,” says Andreas Lindblom, Managing Partner and Co-founder.
Life science – investments that make a difference
Sciety’s focus on life science and health tech is no coincidence. The founding team had extensive life science expertise and strong industry connections from the start. Early on, they identified a market gap, with few investors being active in life science despite many promising companies in the industry.
The name Sciety, a combination of “science” and “society”, reflects our driving force: ensuring that important research is not held up in the laboratory but is transformed into products and services that improve people’s health worldwide. By investing in areas where innovations have the potential to revolutionise healthcare, we aim to improve the quality of life for millions of people.
To achieve this goal, we have specialised in life science and developed extensive expertise, which we use to identify promising investment opportunities, monitor market developments, and collaborate with the industry’s leading experts. Life science is also an investment area where returns and impact go hand in hand.
“If you invest in carefully selected life science companies, there’s potential for high returns in an industry that really makes a difference to people’s health and wellbeing. Contributing to companies that have the potential to make a difference in people’s lives is something many investors find important,” says Andreas Lindblom.
Our impact in life science
Sciety’s strength builds on a combination of deep industry expertise and advanced digital infrastructure. We evaluate hundreds of companies annually and carefully select the most promising investment opportunities.
What has happened so far in our history:
- Over 1 billion SEK invested in innovative life science companies
- 26 portfolio companies, of which 9 have been successfully acquired or listed
- A growing network of investors through Sciety Venture Partners
- Strategic partnerships with leading industry players
Our portfolio companies develop vital innovations in diagnostics, medicine, and healthcare. One example is the medtech company Capitainer, which has developed an intelligent solution for self-sampling of blood, plasma, and urine. The collaboration with Sciety resulted in an investment that enabled Capitainer to scale up production and increase sales. Capitainer’s long-term partnership with Sciety has also been crucial for the company’s strategic expansion in the US market. Read more about Capitainers collaboration with Sciety.
Other examples of companies we have invested in include Cartana, Neogap, and Akiram Therapeutics. Read more about our portfolio companies.
Together we shape the future of health
In the coming years, we look forward to continuing to work towards our vision – ensuring that innovations reach their full potential and that scientific breakthroughs become available to people worldwide. With a strengthened team and new strategic initiatives, we continue to drive development within Swedish life science – creating opportunities both for investors and for the life science companies driving development.
Want to join the journey?
- For investors: Become part of Sciety Venture Partners and gain access to carefully selected investment opportunities in life science. Read more about members of Sciety Venture Partners.
- For life science companies: Let’s explore how we can support your growth journey with capital and strategic expertise. Read more about financing.
- Follow our development by subscribing to our newsletter.
Disclaimer: The information contained in our emails and communications is intended for informational purposes only and is not intended to constitute advice or recommendations on any investment. We do not guarantee the accuracy, completeness, timeliness, or suitability of any information provided. Please note that our communications are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation. In particular, our communications are not intended for persons in the United States or Australia. We do not accept any liability for any loss or damage arising from the use of our communications, including but not limited to any investment decisions made based on the information provided. Furthermore, please note that any investment in private companies involves a high degree of risk and is not suitable for all investors. Before making any investments, you must read and accept our general terms and conditions for investments, which can be found at the following link: General Terms and Conditions for Investments.
